Glycosylation Profiling of the Neoplastic Biomarker Alpha Fetoprotein through Intact Mass Protein Analysis.
AFP-L3 proteoforms
core fucose
fucosylation
high-resolution mass spectrometry
intact protein analysis
Journal
Journal of proteome research
ISSN: 1535-3907
Titre abrégé: J Proteome Res
Pays: United States
ID NLM: 101128775
Informations de publication
Date de publication:
06 01 2023
06 01 2023
Historique:
pubmed:
22
12
2022
medline:
10
1
2023
entrez:
21
12
2022
Statut:
ppublish
Résumé
Elevated serum alpha-fetoprotein (AFP) can be observed in liver cirrhosis and hepatocellular carcinoma (HCC). The glycosylation patterns of AFP have been shown to differentiate these conditions, with AFP glycoforms with core fucosylation (AFP-L3) serving as a malignancy risk predictor for HCC. We have developed a method to detect endogenously present AFP proteoforms and to quantify the relative abundance of AFP-L3 glycoforms (AFP-L3%) in serum samples. This method consists of immune enrichment of endogenous AFP, followed by liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) intact protein analysis of AFP. Data are available via ProteomeXchange with identifier PXD038606. Based on the AFP profiles in authentic patient serum samples, we have identified that the frequently observed AFP glycoforms without core fucosylation (AFP-L1) are G2S2 and G2S1, and common AFP-L3 glycoforms are G2FS1 and G2FS2. The intensities of glycoforms in the deconvoluted spectrum are used to quantify AFP-L3% in each sample. The method evaluation included reproducibility, specificity, dilution integrity, and comparison of AFP-L3% with a lectin-binding gel shift electrophoresis (GSE) assay. The AFP-L1 and AFP-L3 proteoforms were reproducibly identified in multiple patient serum samples, resulting in reproducible AFP-L3% quantification. There was considerable agreement between the developed LC-HRMS and commercial GSE methods when quantifying AFP-L3% (Pearson
Identifiants
pubmed: 36541409
doi: 10.1021/acs.jproteome.2c00656
pmc: PMC9830635
doi:
Substances chimiques
alpha-Fetoproteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-234Commentaires et corrections
Type : ErratumIn
Références
Br J Cancer. 1999 Dec;81(7):1188-95
pubmed: 10584881
Leukemia. 2022 Aug;36(8):2076-2085
pubmed: 35610346
Protein J. 2017 Feb;36(1):1-6
pubmed: 28108801
J Proteome Res. 2008 Jun;7(6):2222-33
pubmed: 18479159
Electrophoresis. 1989 Aug-Sep;10(8-9):562-7
pubmed: 2478360
J Proteome Res. 2022 Apr 1;21(4):1083-1094
pubmed: 35286803
Ultrasound Obstet Gynecol. 2013 Jul;42(1):15-33
pubmed: 23765643
Adv Exp Med Biol. 2012;736:313-23
pubmed: 22161337
Science. 2021 Feb 26;371(6532):
pubmed: 33361116
Front Neurosci. 2021 Jan 13;14:625348
pubmed: 33519371
J Proteome Res. 2022 Jun 3;21(6):1548-1557
pubmed: 35536554
ACS Chem Neurosci. 2022 Jun 15;13(12):1719-1726
pubmed: 35640092
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
EMBO J. 2013 May 15;32(10):1478-88
pubmed: 23584533
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34752419
Proteomics Clin Appl. 2018 Nov;12(6):e1800062
pubmed: 29888876
Nat Rev Mol Cell Biol. 2020 Dec;21(12):729-749
pubmed: 33087899
J Clin Oncol. 2022 Jun 1;40(16):1816-1837
pubmed: 35439025
Glycoconj J. 1997 Aug;14(5):569-76
pubmed: 9298689
Clin Chem. 2018 Aug;64(8):1230-1238
pubmed: 29875214
J Proteome Res. 2010 Oct 1;9(10):4888-96
pubmed: 20731380
N Engl J Med. 1993 Jun 24;328(25):1802-6
pubmed: 7684823
Nat Rev Nephrol. 2019 Jun;15(6):346-366
pubmed: 30858582
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Br J Cancer. 2000 Nov;83(10):1330-7
pubmed: 11044358
Cell. 2015 Jun 18;161(7):1619-32
pubmed: 26091039
Open Access J Urol. 2011 Dec 30;4:1-8
pubmed: 24198649